Peptide Registry

Vials

Capsules

Liquids

a vial of ovagen 20mg
an info card for OVAGEN

Ovagen

$49.00

  • Contents: Ovagen (Glu-Asp-Leu; EDL tripeptide)
  • Form: Lyophilized powder
  • Purity: >99%
Quantity Discount Price
1 - 3 - $49.00
4 - 7 10% $44.10
8 + 18% $40.18
SKU: N/A Category: Brand:

Description

Ovagen is a synthetic tripeptide bioregulator with the sequence Glu-Asp-Leu (EDL), developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Its primary tissue targets are hepatocytes and gastrointestinal epithelial cells — a dual hepatic-GI tissue profile that distinguishes it within the Khavinson specialty research peptide series. Like other bioregulators in this class, Ovagen enters the cell nucleus and interacts with specific DNA promoter regions to modulate gene expression.

Chemical Information

  • Chemical Name: Ovagen (Khavinson ovarian tissue-derived tripeptide bioregulator)
  • Also Known As: Ovagen peptide complex
  • Compound Class: Short-chain synthetic tripeptide; tissue-specific epigenetic bioregulator (Khavinson series)
  • Sequence: Not established in public literature
  • Molecular Formula: Not established in public literature
  • Molecular Weight: Not established in public literature (consistent with the broader Khavinson class of low molecular weight peptides, <10,000 Da)
  • CAS Number: Not established in public literature

Applications

  • Ovarian tissue-specific gene regulation research. Ovagen is modeled on ovarian tissue and is proposed to act via direct peptide-DNA interaction within ovarian cell nuclei, modulating expression of genes involved in reproductive tissue regulation — a mechanism shared with other tissue-targeted Khavinson bioregulators such as Cartalax (chondrocytes) and Cardiogen (cardiomyocytes)
  • Reproductive endocrinology and ovarian function research. Published Khavinson-network literature on tissue-specific bioregulators has examined organ-directed gene programs in matched tissue systems. Ovagen is studied within this framework for ovarian-directed effects
  • Cross-tissue bioregulator specificity research. Because Ovagen is proposed to share its intranuclear DNA-interaction mechanism with other short-chain Khavinson peptides, it is used alongside tissue-matched and mismatched bioregulators to test whether reported gene-regulatory effects are tissue-restricted or tissue-general

Storage and Handling

Store lyophilized powder under refrigeration (2-8C), protected from heat, light, and moisture. As a short-chain peptide, Ovagen is susceptible to proteolytic degradation once reconstituted. Reconstitute immediately before use, keep reconstituted solution refrigerated, and avoid repeated freeze-thaw cycles.

Compliance Notice

Ovagen is for laboratory research use only. It is not for human or veterinary use and carries no therapeutic, diagnostic, or clinical indication. FDA has not evaluated this product. By purchasing this product, the buyer confirms that they will follow appropriate institutional safety procedures and use it exclusively for controlled research.

Frequently Asked Questions

What is Ovagen?

Ovagen (EDL) is a synthetic tripeptide bioregulator from the Khavinson series targeting hepatocytes and gastrointestinal epithelial cells. It enters cell nuclei and modulates gene expression at specific DNA promoter regions, with documented targets including CYP450 family enzymes, glutathione S-transferase genes, and GI mucosal barrier proteins. All published evidence is preclinical.

How does Ovagen differ from Livagen in liver research?

Both are Khavinson bioregulators with liver tissue as a primary target, but their second tissue focus diverges entirely. Livagen (KEDA) targets lymphocytes alongside hepatocytes — its liver research connects to immune cell biology and chromatin decondensation in aged leukocyte populations. Ovagen (EDL) targets gastrointestinal epithelium alongside hepatocytes — its research spans hepatic metabolic enzyme gene regulation and GI mucosal barrier biology. Researchers select between them based on whether the study requires hepatic-immune or hepatic-GI dual tissue observation.

Why is PepT1/PepT2 transporter uptake relevant to Ovagen's GI research applications?

PepT1 and PepT2 are di/tripeptide transporters expressed at high levels on intestinal epithelial cells — the same transport system relevant in KPV research in the GI context. Their active transport of Ovagen across epithelial membranes provides a defined cellular uptake mechanism in GI models, which affects concentration-response relationships and tissue distribution in intestinal research designs. Researchers using Ovagen in GI epithelial models need to account for this transporter-mediated uptake rather than assuming passive diffusion kinetics.

Related products